Age does not appear to be a barrier to aggressive therapy with paclitaxel and carboplatin in women with ovarian cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1224, 2000-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

QOL better with carboplatin + paclitaxel for ovarian cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 498, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Carboplatin: first-line therapy for ovarian cancer?

By  

Inpharma, Vol. 1, Iss. 1352, 2002-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer

By Rosanò Laura   Cianfrocca Roberta   Spinella Francesca   Di Castro Valeriana   Natali Pier G.   Bagnato Anna  

Canadian Journal of Physiology and Pharmacology, Vol. 88, Iss. 6, 2010-06 ,pp. : 676-681

NRC Research Press

Access to resources Recommend Favorite

Paclitaxel poliglumex for ovarian cancer

By Galic Vijaya L   Wright Jason D   Lewin Sharyn N   Herzog Thomas J  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 813-821

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel + carboplatin, docetaxel alone, for endometrial cancer

By  

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite